Sources: Silver Lake acquires a one-third stake in GoodRx, a US-based online drug price comparison shopping company, at about a $2.8B valuation
Context & Ripple Effects
Silver Lake's move is a classic pre-IPO growth bet: the firm takes a one-third position in GoodRx, a drug price-comparison and coupon platform, at roughly a $2.8B valuation — a private-market price set two years before the company's listing. When GoodRx later disclosed its amended S-1, it confirmed Silver Lake had put in $100M alongside founder stock grants, positioning the firm as the anchor private backer heading into the offering.
The payoff arc matters for how you read this deal: GoodRx priced its IPO at $33 a share, valuing it near $12.7B, then closed up more than 50% at a $19.4B market cap — meaning Silver Lake's entry valuation was marked up roughly sevenfold by the public market within two years.
First-order effects
- GoodRx gains a deep-pocketed institutional holder with a one-third stake, giving it capital and sponsor credibility ahead of an eventual public listing rather than forcing an early sale.
- Silver Lake locks in exposure to a consumer health-tech asset at a $2.8B private valuation — the low-water mark against which its eventual exit returns will be measured.
Second-order effects
- The deal validates the online pharmacy and prescription-savings category for other investors: Ro follows with a $500M raise at a $5B valuation, while UnitedHealth moves to consolidate the space by acquiring DivvyDose, a PillPack and CareZone competitor.
- Rival pharmacies and PBM-adjacent players face a funded price-transparency intermediary with national reach, pressuring them to build or buy their own discount and comparison capabilities.
Third-order effects
- The pattern — a large PE minority stake in a consumer health platform followed by a public listing at a far higher mark — feeds the widening gap between private entry valuations and public clearing prices, and gives sponsors a repeatable template.
- For Silver Lake specifically, the playbook scales upward: the same firm later pursues full take-privates, including reported talks over Workday and the consortium acquisition of Electronic Arts, shifting from minority growth stakes to control deals as its health-tech and software thesis matures.
The trend: Private equity is increasingly anchoring consumer health-tech platforms years before their public listings, with Silver Lake's GoodRx stake an early instance of a playbook that has since scaled into multibillion-dollar take-privates.